FIG. 3.

Treatment with anti-IL-4 antibody does not reverse the exacerbative effects of CTLA4 blockade in L. major-infected BALB/c mice. Groups of five mice were infected with 2 × 10⁶ promastigotes of L. major and injected on days 0 and 7 with saline (□) and 0.3 mg of anti-CTLA4 MAb (■). Other groups of mice were treated with 1.0 mg of neutralizing anti-IL-4 MAb 11B11 alone (○) or anti-CTLA4 MAb in combination with anti-IL-4 MAb (●). Shown are the mean ± the SEM footpad thicknesses at weekly intervals.